← teresacarles.com


"Buy maxolon 10mg low cost, gastritis diet 9 month."

By: John Theodore Geneczko, MD

  • Assistant Professor of Medicine


Individuals with any of these childhood-onset dis­ orders may exhibit impulsive aggressive outbursts gastritis garlic discount 10mg maxolon visa. While indi­ viduals with conduct disorder can exhibit impulsive aggressive outbursts gastritis attack buy maxolon without a prescription, the form of ag­ gression characterized by the diagnostic criteria is proactive and predatory gastritis diet kits buy genuine maxolon on line. Aggression in oppositional defiant disorder is typically characterized by temper tantrums and verbal ar­ guments with authority figures chronic gastritis dogs discount maxolon 10mg line, whereas impulsive aggressive outbursts in intermittent explosive disorder are in response to a broader array of provocation and include physical assault. The level of impulsive aggression in individuals with a history of one or more of these disorders has been reported as lower than that in comparable individuals whose symptoms also meet intermittent explosive disorder Criteria A through E. Accordingly, if Criteria A through E are also met, and the impulsive aggressive outbursts warrant inde­ pendent clinical attention, a diagnosis of intermittent explosive disorder may be given. Comorbidity Depressive disorders, anxiety disorders, and substance use disorders are most commonly comorbid with intermittent explosive disorder. In addition, individuals with antisocial personality disorder or borderline personality disorder, and individuals with a history of disorders with disruptive behaviors. A repetitive and persistent pattern of behavior in which the basic rights of others or ma­ jor age-appropriate societal norms or rules are violated, as manifested by the presence of at least three of the following 15 criteria in the past 12 months from any of the cate­ gories below, with at least one criterion present in the past 6 months: Aggression to People and Animals 1. Has deliberately engaged infire setting with the intention of causing serious damage. Often stays out at night despite parental prohibitions, beginning before age 13 years. Has run away from home overnight at least twice while living in the parental or pa­ rental surrogate home, or once without returning for a lengthy period. The disturbance in behavior causes clinically significant impairment in social, aca­ demic, or occupational functioning. If the individual is age 18 years or older, criteria are not met for antisocial personality disorder. Specify if: With limited prosocial emotions: To qualify for this specifier, an individual must have dis­ played at least two of the following characteristics persistently over at least 12 months and in multiple relationships and settings. These characteristics reflect the individual’s typical pattern of interpersonal and emotional functioning over this period and not just occasional occurrences in some situations. Thus, to assess the criteria for the specifier, multiple infor­ mation sources are necessary. In addition to the individual’s self-report, it is necessary to consider reports by others who have known the individual for extended periods of time. Lack of remorse or guilt: Does not feel bad or guilty when he or she does some­ thing wrong (exclude remorse when expressed only when caught and/or facing punishment). The individual shows a general lack of concern about the negative consequences of his or her actions. For example, the individual is not remorseful after hurting someone or does not care about the consequences of breaking rules. Callous—lack of empathy: Disregards and is unconcerned about the feelings of others. The person appears more concerned about the effects of his or her actions on himself or herself, rather than their effects on others, even when they result in substantial harm to others. Unconcerned about performance: Does not show concern about poor/problem­ atic performance at school, at work, or in other important activities. The individual does not put forth the effort necessary to perform well, even when expectations are clear, and typically blames others for his or her poor performance. Shallow or deficient affect: Does not express feelings or show emotions to others, except inways that seem shallow, insincere, or superficial. Specify current severity: Mild: Few if any conduct problems in excess of those required to make the diagnosis are present, and conduct problems cause relatively minor harm to others. Moderate: the number of conduct problems and the effect on others are intermediate between those specified in “mild”and those in “severe”. Severe: Many conduct problems in excess of those required to make the diagnosis are present, or conduct problems cause considerable harm to others. Subtypes Three subtypes of conduct disorder are provided based on the age at onset of the disorder. Onset is most accurately estimated with information from both the youth and the care­ giver; estimates are often 2 years later than actual onset. An unspecified-onset subtype is designated when there is in­ sufficient information to determine age at onset. In childhood-onset conduct disorder, individuals are usually male, frequently display physical aggression toward others, have disturbed peer relationships, may have had op­ positional defiant disorder during early childhood, and usually have symptoms that meet full criteria for conduct disorder prior to puberty. Individuals with childhood-onset type are more likely to have per­ sistent conduct disorder into adulthood than are those with adolescent-onset type. As compared with individuals with childhood-onset type, individuals with adolescent-onset conduct disorder are less likely to display aggressive behaviors and tend to have more normative peer relationships (although they often display conduct problems in the com­ pany of others). These individuals are less likely to have conduct disorder that persists into adulthood. The ratio of males to females with conduct disorder is more balanced for the adolescent-onset type than for the childhood-onset type. Specifiers A minority of individuals with conduct disorder exhibit characteristics that qualify for the "with limited prosocial emotions" specifier. The indicators of this specifier are those that have often been labeled as callous and unemotional traits in research. Other personality features, such as thrill seeking, fearlessness, and insensitivity to punishment, may also dis­ tinguish those with characteristics described in the specifier. Individuals with character­ istics described in this specifier may be more likely than other individuals with conduct disorder to engage in aggression that is planned for instrumental gain. Individuals with conduct disorder of any subtype or any level of severity can have characteristics that qual­ ify for the specifier "with limited prosocial emotions," although individuals with the spec­ ifier are more likely to have childhood-onset type and a severity specifier rating of severe. Although the validity of self-report to assess the presence of the specifier has been sup­ ported in some research contexts, individuals with conduct disorder with this specifier may not readily admit to the traits in a clinical interview. Thus, to assess the criteria for the specifier, multiple information sources are necessary. Diagnostic Features the essential feature of conduct disorder is a repetitive and persistent pattern of behavior in which the basic rights of others or major age-appropriate societal norms or rules are vi­ olated (Criterion A). These behaviors fall into four main groupings: aggressive conduct that causes or threatens physical harm to other people or animals (Criteria A1-A7); non­ aggressive conduct that causes property loss or damage (Criteria A8-A9); deceitfulness or theft (Criteria A10-A12); and serious violations of rules (Criteria A13-A15). Three or more characteristic behaviors must have been present during the past 12 months, with at least one behavior present in the past 6months. The disturbance in behavior causes clinically significant impairment in social, academic, or occupational functioning (Criterion B). The behavior pattern is usually present in a variety of settings, such as home, at school, or in the community. Because individuals with conduct disorder are likely to minimize their conduct problems, the clinician often must rely on additional informants. Individuals with conduct disorder often initiate aggressive behavior and react aggres­ sively to others. They may display bullying, threatening, or intimidating behavior (includ­ ing bullying via messaging on Web-based social media) (Criterion Al); initiate frequent physical fights (Criterion A2); use a weapon that can cause serious physical harm. Physical violence may take the form of rape, assault, or, in rare cases, homicide. Individuals with conduct disorder may also frequently commit serious violations of rules. Children with conduct disorder often have a pat­ tern, beginning before age 13 years, of staying out late at night despite parental prohi­ bitions (Criterion A13). Children may also show a pattern of running away from home overnight (Criterion A14). To be considered a symptom of conduct disorder, the running away must have occurred at least twice (or only once if the individual did not return for a lengthy period). Runaway episodes that occur as a direct consequence of physical or sex­ ual abuse do not typically qualify for this criterion. Children with conduct disorder may often be truant from school, beginning prior to age 13 years (Criterion A15).


  • Costello syndrome
  • Cerebral aneurysm
  • Progressive kinking of the hair, acquired
  • Parathyroid neoplasm
  • Biliary atresia, extrahepatic
  • Glycogenosis type VII
  • Microtia, meatal atresia and conductive deafness
  • Lowry Yong syndrome
  • Hypocalcinuric hypercalcemia, familial type 1

proven 10 mg maxolon

To maintain remission after a mild to chronic gastritis juice generic 10mg maxolon mastercard moderate inflammatory exacerbation of proctitis or proctosigmoiditis gastritis extreme pain order cheap maxolon line, consider the following options gastritis diet øàðèêè discount maxolon 10 mg fast delivery, taking into account the person’s preferences: r • a topical aminosalicylate alone (daily or intermittent) or s r • an oral aminosalicylate plus a topical aminosalicylate (daily or intermittent) or s • an oral aminosalicylate alone gastritis lymphoma discount 10 mg maxolon with amex, explaining that this may not be as effective as combined treatment or an intermittent topical aminosalicylate alone. Consider oral azathioprine or oral mercaptopurine to maintain remission: • after two or more inflammatory exacerbations in 12 months that require treatment with systemic corticosteroids or • if remission is not maintained by aminosalicylates. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. To maintain remission after a single episode of acute severe ulcerative colitis: u u • consider oral azathioprine or oral mercaptopurine • consider oral aminosalicylates in people who cannot tolerate or who decline azathioprine and/or mercaptopurine, or in whom azathioprine and/or mercaptopurine are contraindicated. Consider a once-daily dosing regimen for oral aminosalicylates when used for maintaining remission. Take into account the person’s preferences, and explain that once-daily dosing can be more effective, but may result in more side effects. When caring for a pregnant woman with ulcerative colitis: • Ensure effective communication and information-sharing across specialties (for example, primary care, obstetrics and gynaecology, and gastroenterology). Include information relevant to a potential admission for an acute severe inflammatory exacerbation. Consider monitoring bone health in children and young people with ulcerative colitis in the following circumstances: • during chronic active disease • after treatment with systemic corticosteroids • after recurrent active disease. Monitor the height and body weight of children and young people with ulcerative colitis against expected values on centile charts (and/or z scores) at the following intervals according to disease activity: • every 3–6 months: o if they have an inflammatory exacerbation and are approaching or undergoing puberty or o if there is chronic active disease or o if they are being treated with systemic corticosteroids • every 6 months during pubertal growth if the disease is inactive • every 12 months if none of the criteria above are met. Consider referral to a secondary care paediatrician for pubertal assessment and investigation of the underlying cause if a young person with ulcerative colitis: • has slow pubertal progress or • has not developed pubertal features appropriate for their age. What is the clinical and cost effectiveness of prednisolone compared with aminosalicylates for the induction of remission for people with moderate ulcerative colitisfi What is the clinical and cost effectiveness of prednisolone plus an aminosalicylate compared with beclometasone plus an aminosalicylate for induction of remission for people with moderate ulcerative colitisfi What are the benefits, risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroidsfi What is the clinical and cost effectiveness of regular maintenance treatment compared with no regular treatment (but rapid standard treatment if a relapse occurs) in specific populations with mild to moderate ulcerative colitisfi To develop and validate a risk tool that predicts the likelihood of needing surgery for adults admitted to hospital with acute severe ulcerative colitis. All recommendations relate to adults, children and young people unless specified otherwise. These terms are defined as follows: • adults: 18 years or older • children: 11 years or younger • young people: 12 to 17 years. Severity of ulcerative colitis Mild, moderate and severe In this guideline, the categories of mild, moderate and severe are used to describe ulcerative colitis: • In adults these categories are based on the Truelove and Witts’ severity index (see Table 8). Table 8: Truelove and Witts’ severity index Mild Moderate Severe Bowel movements Fewer than 4 4–6 6 or more plus at least (no. Rectal bleeding None 0 Small amount only, in less than 50% of stools 10 Small amount with most stools 20 Large amount (50% of the stool content) 30 3. Stool consistency of most stools Formed 0 Partially formed 5 Completely unformed 10 4. Inflammation affecting the rectum alone may be referred to as proctitis; proctosigmoiditis if the rectum and sigmoid colon are affected; left-sided colitis if the inflammation extends proximally from the rectum to no further than the splenic flexure; sub-total colitis if the inflammation extends beyond the splenic flexure, but does not affect the whole colon; total colitis, or pan-colitis, if the entire colon is affected. The natural course of ulcerative colitis is characterised by periods where symptoms are present, interspersed with periods of clinical remission. Mild attacks are defined as those where the stool frequency is less than four times per day, with only small amounts of blood. Treatment of these exacerbations – induction of remission – may involve a range of different drug types, administered by different routes and at different doses. These include: • choice of drug • site and mechanism of drug release – for orally administered 5-aminosalicylic acid preparations • route of administration – which may include combinations of different routes (eg oral and rectal administration) • dose. There are also patient-related factors which may influence the choice of treatment for induction of remission, which would include: • clinical severity of the exacerbation • extent of inflammation • patient preference • dosing regimens, for example, those which may enhance adherence to treatment. The most widely used drugs in this situation are corticosteroids and aminosalicylate preparations of which 5-aminosalicylic acid is the active moiety. Depending on the preparation, 5-aminosalicylic acid is released through differing mechanisms including loss of integrity of an outer coating or cleavage of a diazo bond from a pro-drug. The aim of this release, in people with ulcerative colitis, is to deliver adequate levels of 5-aminosalicylic acid to the colon and rectum. Systemically bioavailable corticosteroids, such as prednisolone, have been widely used, but concern remains about their side effects. Orally administered beclometasone has topical mucosal activity, but is extensively metabolised with less systemic bioavailability. Immunomodulator drugs (azathioprine, mercaptopurine, ciclosporin, tacrolimus and methotrexate) are also used. There is considerable variation and debate about appropriate outcome measures in studies examining induction of remission. Acute severe ulcerative colitis is regarded as a medical emergency and requires hospital admission for intravenous corticosteroids and prophylaxis against venous thromboembolism. Evidence relating to the use of systemic corticosteroids and ciclosporin was reviewed in this chapter. Parameters that would help in assessing response, and in selecting patients at higher risk of colectomy (and therefore who may benefit from escalation of medical therapy), are examined in detail in section 5. A cross in the box indicates evidence was found and the evidence has been reviewed in this chapter an empty box indicates no evidence was found. Ulcerative colitis Inducing remission in people with ulcerative colitis the reviews for the induction of remission in people with mild to moderate ulcerative colitis are presented in the following order: • Topical aminosalicylates (section 5. For all the reviews in this chapter an author defined definition of the clinical, endoscopic, clinical and endoscopic remission and clinical improvement was used. There are an extensive number of different indices used in the published literature and many of these indices are not validated. The bias associated with using the author’s definitions was taken into account when analysing the data. It was thought that any drug taking longer than 12 weeks to have an effect would not be suitable for the induction of remission and more likely to be maintenance of remission treatment. The following subgroups were considered for subgroup analysis in the event of heterogeneity in the meta-analysis: • Disease severity: mild to moderate • Dose • Disease extent: proctitis, proctosigmoiditis, left-sided ulcerative colitis, extensive ulcerative colitis • Age (adults, children and young people) • Formulation (foam, enema, suppository, tablet, capsule). The reviews in this section are topical aminosalicylates versus placebo (section 5. Foam enemas may be more clinically effective at increasing clinical improvement compared to liquid enemas at 0fi2 weeks but there may be no clinically important difference at >2fi4 or at > 6fi8 weeks [very low to moderate quality evidence, 1 study, N=233; 2 studies, N=281;1 study, N=48]. Important outcomes There may be no clinical difference in endoscopic remission rates between foam and liquid enemas, the direction of the estimate of effect favoured the liquid enema although liquid enemas may have a greater clinical and endoscopic remission rate compared to foam enemas at 2fi4 weeks [very low to low quality evidence, 3 studies, N=796;1 study, N=195]. There may be no clinically important difference in adverse or serious adverse event rates between foam and liquid enemas [very low to low quality evidence,2 studies, N=606;1 study, N=373]. Important outcomes Suppositories may have a higher endoscopic remission rate compared to liquid enemas at 0fi2 weeks, but may not at 2fi4 weeks [very low quality evidence,1 study, N=39]. Important outcomes There may be no clinically difference in endoscopic remission rates between doses apart from 1g versus 4g at 0fi2 weeks where the higher dose may be clinically more effective [low to very low quality evidence, 1 study, N=63;3 studies, N=226;2 studies, N=202;2 studies, N=203]. Conversely there may be no clinical difference in clinical and endoscopic remission rates at 0fi2 weeks, but the lower dose of 1g may be clinically more effective at 2fi4 weeks compared to 2g [very low quality evidence,1 study, N=25]. There may be no clinical difference in adverse events between doses [2 studies, N=88]. The reviews in this section are topical corticosteroids versus placebo (section 5. Only the drug related adverse events were reported which were 20/54 (37%) for the 2mg budesonide liquid enema group, 24/60 (40%) for the 8mg group and 18/57 (32%) for the placebo group. Many were gastrointestinal complaints (mild) and two patients got acne (1 in each treatment group). Subgroup analysis A high heterogeneity value was found (81%) for the budesonide enema versus prednisolone disodium phosphate enema comparison and endoscopic remission at >2fi4 weeks outcome. Both studies use the definition of a grade of 0 for endoscopic remission and use the same indexes to measure it (According to Truelove & Richards. Important outcomes Topical steroids are more clinically effective at increasing endoscopic and clinical and endoscopic remission rates compared to placebo [very low quality evidence,1 study, N=171]. There may be no clinical difference in serious adverse events between topical steroids and placebo [very low quality evidence, 1 study, N=171]. Important outcomes There is no clinically important difference in endoscopic remission rates (>2fi4 weeks)or in adverse or serious adverse event rates between foam and liquid steroid enemas[very low to low quality evidence,1 study, N=438;1 study, N=535; 1 study, N=535]. Important outcomes There may be no clinical difference in increasing endoscopic,clinical and endoscopic remission or in adverse or serious adverse event rates between any of the budesonide enemas doses, [very low quality evidence,1 study, N=114;1 study, N=149;1 study, N=114].

Proven 10 mg maxolon. Irritable Bowel Syndrome (IBS) Everything You Need To Know!.

order maxolon online now

Effect of low level laser therapy in rheumatoid arthritis patients with carpal tunnel syndrome gastritis hypertrophic order maxolon 10mg with mastercard. Clinical outcome and neurophysiological results of low power laser irradiation in carpal tunnel syndrome gastritis kronik cheap 10mg maxolon with mastercard. Laser therapy in the treatment of carpal tunnel syndrome: a randomized controlled trial gastritis diet cooking cheap 10mg maxolon mastercard. Double-blind randomized controlled trial of low-level laser therapy in carpal tunnel syndrome symptoms of upper gastritis order generic maxolon line. Low-level laser in the treatment of carpal tunnel syndrome: clinical, electrophysiological, and ultrasonographical evaluation. Comparison of splinting and splinting plus low level laser therapy in idiopathic carpal tunnel syndrome. Carpal tunnel syndrome treated with a diode laser: a controlled treatment of the transverse carpal ligament. Carpal tunnel syndrome pain treated with low-level laser and microamperes transcutaneous electric nerve stimulation: A controlled study. Study of long term effects of laser therapy versus local corticosteroid injection in patients with carpal tunnel syndrome. The effects of low level laser in clinical outcome and neurophysiological results of carpal tunnel syndrome. Treatment of carpal tunnel syndrome with polarized polychromatic noncoherent light (Bioptron light): A preliminary, prospective, open clinical trial. Manipulative and multimodal therapy for upper extremity and temporomandibular disorders: a systematic review. The use of joint mobilization to improve clinical outcomes in hand therapy: a systematic review of the literature. A pilot study comparing two manual therapy interventions for carpal tunnel syndrome. Conservative treatment of carpal tunnel syndrome: comparison between laser therapy and Fascial Manipulation((R)). Heightened pain sensitivity in individuals with signs and symptoms of carpal tunnel syndrome and the relationship to clinical outcomes following a manual therapy intervention. Reliability and efficacy of the new massage technique on the treatment in the patients with carpal tunnel syndrome. Comparison of a targeted and general massage protocol on strength, function, and symptoms associated with carpal tunnel syndrome: a randomized pilot study. Physiological adjustments to stress measures following massage therapy: a review of the literature. Effectiveness of manual therapy or pulsed shortwave diathermy in addition to advice and exercise for neck disorders: a pragmatic randomized controlled trial in physical therapy clinics. Heat distribution in the lower leg from pulsed short-wave diathermy and ultrasound treatments. Short-term effects of local microwave hyperthermia on pain and function in patients with mild to moderate carpal tunnel syndrome: a double blind randomized sham-controlled trial. Short-term effectiveness of short-wave diathermy treatment on pain, clinical symptoms, and hand function in patients with mild or moderate idiopathic carpal tunnel syndrome. Ultrasound treatment for treating the carpal tunnel syndrome: randomised “sham” controlled trial. The comparison of ultrasound treatment and local steroid injection plus splinting in the carpal tunnel syndrome: a randomized controlled trial. Comparative effectiveness of ultrasound and paraffin therapy in patients with carpal tunnel syndrome: a randomized trial. Effects of placebo-controlled continuous and pulsed ultrasound treatments on carpal tunnel syndrome: a randomized trial. Efficacy of some combined conservative methods in the treatment of carpal tunnel syndrome: a randomized controlled clinical and electrophysiological trial. Determination of sensitive electrophysiologic parameters at follow-up of different steroid treatments of carpal tunnel syndrome. Phonophoresis of dexamethasone sodium phosphate may manage pain and symptoms of patients with carpal tunnel syndrome. Corticosteroid iontophoresis to treat carpal tunnel syndrome: A doublefiblind randomized controlled trial. Evaluation of iontophoresis and local corticosteroid injection in the treatment of carpal tunnel syndrome. Intracarpal steroid injection is safe and effective for short term management of carpal tunnel syndrome. Injection with methylprednisolone proximal to the carpal tunnel: randomised double blind trial. Injection with methylprednisolone in patients with the carpal tunnel syndrome: a randomised double blind trial testing three different doses. Comparison of open carpal tunnel release and local steroid treatment outcomes in idiopathic carpal tunnel syndrome. Local steroid treatment in idiopathic carpal tunnel syndrome: short and long-term efficacy. A novel approach of local corticosteroid injection for the treatment of carpal tunnel syndrome. A systematic review of anti-inflammatories for mild to moderate carpal tunnel syndrome. Surgical decompression versus local steroid injection in carpal tunnel syndrome: a one-year, prospective, randomized, open, controlled clinical trial. The efficacy of local steroid injections in idiopathic carpal tunnel syndrome: a double blind study. Session #104: Advancements in Upper Extremity Ergonomics and Neuromusculoskeletal Disorders. Primary care management of patients with carpal tunnel syndrome referred to surgeons: are non-operative interventions effectively utilisedfi A randomized controlled trial of surgery vs steroid injection for carpal tunnel syndrome. Triamcinolone acetonide vs procaine hydrochloride injection in the management of carpal tunnel syndrome: randomized placebo-controlled study. Comparison of surgical decompression and local steroid injection in the treatment of carpal tunnel syndrome: 2-year clinical results from a randomized trial. Randomised controlled trial of local corticosteroid injections for carpal tunnel syndrome in general practice. Comparison of local steroid injection into carpal tunnel via proximal and distal approach in patients with carpal tunnel syndrome. Effects of perineural steroid injections on median nerve conduction during the carpal tunnel release. Evaluation of effectiveness of local insulin injection in none insulin dependent diabetic patient with carpal tunnel syndrome. Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpal tunnel syndrome. Efficacy of botulinum toxin type A in the relief of Carpal tunnel syndrome: A preliminary experience. Endoscopic release in carpal tunnel syndrome: analysis of clinical results in 200 cases. Endoscopic carpal tunnel release: a prospective analysis of factors associated with unsatisfactory results. The Chow technique of endoscopic release of the carpal ligament for carpal tunnel syndrome: four years of clinical results. A 12-year experience using the Brown two-portal endoscopic procedure of transverse carpal ligament release in 14,722 patients: defining a new paradigm in the treatment of carpal tunnel syndrome. Carpal tunnel release under local anesthesia: evaluation of the outpatient procedure. A systematic review of reviews comparing the effectiveness of endoscopic and open carpal tunnel decompression. A meta-analysis of randomized controlled trials comparing endoscopic and open carpal tunnel decompression. Surgical techniques and return to work following carpal tunnel release: a systematic review and meta-analysis. Is surgical intervention more effective than non-surgical treatment for carpal tunnel syndromefi

Artichaut Commun (Artichoke). Maxolon.

  • What other names is Artichoke known by?
  • Are there safety concerns?
  • How does Artichoke work?
  • Preventing alcohol-induced hangover.
  • Upset stomach symptoms such as nausea, vomiting, flatulence (gas), and stomach pain.
  • Dosing considerations for Artichoke.
  • Irritable bowel syndrome, water retention, snakebites, kidney problems, anemia, arthritis, liver problems, preventing gallstones, high blood pressure, and other conditions.
  • High cholesterol.
  • What is Artichoke?

Source: http://www.rxlist.com/script/main/art.asp?articlekey=96817